Updated:
Amryt Pharma plc
Amryt Pharma plc was incorporated in Ireland and publicly lists on the London Stock Exchange (LSE: AMYT) and through American Depositary Shares on the...
Amryt Pharma plc
Amryt Pharma plc was incorporated in Ireland and publicly lists on the London Stock Exchange (LSE: AMYT) and through American Depositary Shares on the Nasdaq (Nasdaq: AMYT). The company's origins trace to a management team led by CEO Dr. Joe Wiley, who previously held roles at Shire and other specialty pharmaceutical firms. Amryt's wealth derives from equity capital raised through public markets, not private family wealth, positioning it as a publicly traded biopharmaceutical firm rather than a family office or asset manager. Amryt's strategy centers on rare disease therapeutics, with a pipeline that spans preclinical through commercial-stage assets. The company's key approved products include Filsuvez (for epidermolysis bullosa) and Waylivra (for familial chylomicronemia syndrome). Amryt generates revenue from product sales in Europe and the United States (per the firm's 2023 annual report). The company invests in clinical development, regulatory filings, and market access expansion across both regions. Amryt has also pursued business development, including the acquisition of novel compounds from third parties. As of its most recent filings, Amryt employed several hundred professionals across its Dublin headquarters and additional offices in the U.S. and Europe. The company does not disclose AUM or deployment figures in the family-office context; its financial position is detailed through public earnings reports. May 2024: Amryt announced—per regulatory filings—updated clinical trial data for a lead pipeline candidate, though no material operational events occurred in the prior 24 months that reshape the firm's fundamental strategy. Structurally, Amryt Pharma operates as a publicly traded pharmaceutical company with a board of directors and shareholder base, distinguishing it from the typical family-office or private-equity structure. The firm's capital allocation is governed by corporate finance discipline rather than by a family's private investment mandate, making its governance and strategic posture distinct from the family offices conventionally profiled.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
Ireland
City
Dublin
Corporate office
Dublin, Ireland
Sector focus
Frequently asked questions
Who runs investment decisions at Amryt Pharma?
Investment and capital-allocation decisions are overseen by the board of directors and executive management, led by CEO Dr. Joe Wiley. The company does not have a single designated investment committee separate from its corporate governance structure (per public filings).
How does Amryt Pharma source proprietary deal flow?
Amryt sources drug candidates through internal R&D, in-licensing from academic institutions and biotechnology companies, and acquisitions of distressed or undercapitalized assets. The firm's business development team evaluates preclinical and clinical-stage compounds in the rare disease space (per the firm's annual report).
Is Amryt Pharma structured as a family office or a pharmaceutical firm?
Amryt Pharma is structured as a publicly traded biopharmaceutical company, not a family office. It is subject to public company governance, SEC filings (through ADRs), and shareholder reporting. The firm's capital belongs to public equity holders, not a single family or private group.
Does Amryt Pharma participate in fund commitments or only direct deals?
Amryt Pharma does not act as a fund investor; it engages in direct corporate transactions, including R&D expenditures, licensing agreements, and acquisitions of drug assets or companies. The firm's investment activity is operational rather than allocator-based.
What investment stages does Amryt Pharma typically target?
As a commercial-stage biopharmaceutical firm, Amryt targets assets across clinical development (Phase 2 and Phase 3) and approved marketed products. The company acquires or licenses compounds that can be integrated into its rare-disease pipeline (per the firm's business strategy disclosures).
Which sectors does Amryt Pharma explicitly avoid?
Amryt Pharma explicitly focuses on rare disease therapeutics and does not invest in other therapeutic areas such as oncology, central nervous system disorders, or infectious disease, according to its publicly stated strategy.
Where does the underlying wealth come from?
Amryt Pharma's capital originates from public equity markets through institutional and retail investors, not from a private family fortune. The firm has raised funds through follow-on offerings and debt facilities (per the firm's regulatory filings).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: